Quantcast
Last updated on April 18, 2014 at 15:05 EDT

Latest Upsher-Smith Laboratories Inc. Stories

2014-03-24 16:24:14

MAPLE GROVE, Minn., March 24, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), today announced that it has entered into a definitive agreement under which New Jersey-based Vertical Pharmaceuticals, LLC has acquired Upsher-Smith's rights to Divigel(®) (estradiol gel) 0.1%, Nexa(®) Plus Rx Prenatal Vitamin, and Provella(®), a...

2014-03-12 12:29:03

Qudexy(TM) XR Offers Newest Option for Managing Certain Seizure Disorders and Marks the Company's Entrance into the Epilepsy Therapeutic Area MAPLE GROVE, Minn., March 12, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced it received approval on March 11, 2014 from the U.S. Food and Drug Administration (FDA) for Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth...

2014-03-04 12:25:48

Dietary Supplement Niacin Helps to Maintain Good Cholesterol within a Healthy Range MAPLE GROVE, Minn., March 4, 2014 /PRNewswire/ -- February has passed and with its close comes the end of American Heart Month. But the end of the month should not be the end of proactively supporting heart health. According to the American Heart Association, an estimated 83.6 million American adults have one or more types of Cardiovascular Disease and 98.9 million Americans age 20 and over have high...

2014-03-03 08:33:04

Seizure Clusters Connect(TM) is an Online Community Designed to Provide Support and Resources for Patients and Caregivers MAPLE GROVE, Minn., March 3, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced a new educational program created for patients living with seizure clusters, as well as their families and friends. The initiative--called Seizure Clusters Connect(TM)--uses traditional and social media to offer patients and their caregivers a community for...

2014-01-13 08:30:06

Company Recognizes 2013 Winners of the National Alliance of State Pharmacy Associations' Excellence in Innovation Award MAPLE GROVE, Minn., Jan. 13, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), is pleased to honor the 2013 recipients of the National Alliance of State Pharmacy Associations' (NASPA) Excellence in Innovation Award. Forty-two pharmacists in 41 states were recognized last year. The award is coordinated annually by NASPA and sponsored by Upsher-Smith....

2013-12-10 08:31:19

Impact of Delayed-Dose Administration Results also Announced at the American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 10, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the presentation of new Phase 1 data showing that USL255 (extended-release topiramate) may provide a beneficial treatment option for individuals with difficulty swallowing whole capsules or tablets. Additionally, simulations of data from another Phase 1 study...

2013-12-09 08:30:31

Efficacy and Safety/Tolerability Findings Presented at 2013 American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 9, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today presented results from its global Phase 3 (PREVAIL) study of USL255 (extended-release topiramate), showing that the investigational drug met its primary and secondary endpoints for efficacy and demonstrated favorable safety and tolerability in epilepsy patients with refractory partial-onset...

2013-12-04 16:26:01

CHESTERBROOK, Pa., Dec. 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") announced today that the United States District Court for the District of Delaware ("Court") granted Upsher-Smith Laboratories, Inc.'s ("USL") motion for summary judgment with respect to its attempts to bring a testosterone gel product to market via its 505(b)(2) NDA using Auxilium's Testim® product as its reference listed drug. (Logo:...

2013-12-04 12:26:49

MAPLE GROVE, Minn., Dec. 4, 2013 /PRNewswire/ -- Dietary supplements are dominating the shelves of pharmacy retailers, with brands vying for the attention of health-conscious consumers. In fact, industry experts report that approximately 50% of American adults take dietary supplements. Despite the Dietary Supplement Health and Education Act (DSHEA) governing manufacturing, packaging and holding standards for the dietary supplement industry, it is difficult for consumers to be sure...

2013-11-18 08:30:03

Multiple Presentations Highlight Findings from Phase 3 Trial Investigating USL255 for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures MAPLE GROVE, Minn., Nov. 18, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it will present new research from its epilepsy clinical development program for USL255 (extended-release topiramate) during the American Epilepsy Society's (AES) 67(th) Annual Meeting in Washington, DC,...